Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320722 · ClinicalTrials.gov registry record · Phase 3
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT01320722: Completed Phase 3 study, sponsored by Brigham and Women's Hospital.
NCT01320722 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 242 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01320722, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
The investigators hypothesize that, among non-hypertensive overweight and obese individuals, treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system (RAS) activation, improve endothelial function, and lower blood pressure.
Primary Outcome
Change in RPF in response to captopril is a measure of the vasodilator effect from inhibiting angiotensin II (AngII)- mediated vascular tone and therefore the degree of kidney specific Renin Angiotensin System (RAS) activity. Participants consumed a high sodium diet 3 days prior to the test. Following an 8 hour fast, participants remained in a supine (lying down) position and had an intravenous (IV) catheter inserted in each arm, one for infusion and one for blood collection. An 8 milligrams (mg
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Probenecid
- DRUG Vitamin D ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
What the finished NCT01320722 record still lists
NCT01320722 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01320722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01320722 about?
NCT01320722 is a clinical study titled "Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function". The investigators hypothesize that, among non-hypertensive overweight and obese individuals, treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system (RAS) activation, improve ...
What is the current status of trial NCT01320722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2011-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01320722?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Probenecid (DRUG), Vitamin D ergocalciferol (DRUG).
Who is sponsoring clinical trial NCT01320722?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01320722's enrollment target sits among peer trials
242 1270th of 2000 higher than 729 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia